Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis
Mathew S. Maurer(Alnylam Pharmaceuticals (United States)), Giampaolo Merlini(University of Pavia), Claudio Rapezzi(University of Ferrara), Isabelle Lousada(Amyloidosis Foundation), Sharmila Dorbala(Brigham and Women's Hospital), Marianna Fontana(Amyloidosis Foundation), Sabahat Bokhari(Boston University), Arnt V. Kristen(Heidelberg University), Brian Drachman(Penn Presbyterian Medical Center), Thibaud Damy(Amyloidosis Foundation), Martha Grogan(Mayo Clinic in Arizona), Candida Cristina Quarta(Boston University), Frederick L. Ruberg(Boston University), José Nativi-Nicolau(Jacksonville College), Ronald Witteles(Alnylam Pharmaceuticals (United States))
Cited by 560
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k